QuidelOrtho will trade on the Nasdaq Global Select Market under the symbol “QDEL.”
In combined revenues in 2021 and has approximately 6,000 employees. (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (“Ortho”), creating QuidelOrtho, a leading in vitro diagnostics company. Inspired by a spirit of service, the QuidelOrtho family is committed to enhancing the wellbeing of people worldwide and happy in the knowledge we are making a difference.QuidelOrtho to participate in the William Blair 42nd AnnualĪnnounced completion of the transaction combining
#Ortho quidel full#
Spanning the full spectrum of customers and care – from the largest labs and hospitals to the smallest clinics and in our homes– our diverse suite of diagnostic solutions expand access to reliable answers, providing critical information when and where it is needed most.
#Ortho quidel software#
Our current products fall generally into these categories: (1) visually-read lateral flow, where we are market leaders in infectious disease and reproductive health (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology (3) micro-titer production, with a focus on bone and complement pathway markets (4) fluorescent immunoassay products (Sofia ®) (5) molecular diagnostic products including our flagship Savanna ®, an integrated molecular diagnostic system (6) immunodiagnostics, clinical chemistry and integrated testing systems to serve diagnostic labs of all sizes (VITROS ® Systems) (7) immunodiagnostic donor screening systems and services that drive blood safety (Ortho Summit/VERSEIA ®/VITROS ® Systems) (8) industry-leading pre-transfusion testing that automates blood bank workload (ORTHO VISION Systems) with software to standardize operations, simplify tasks, and improve productivity (ORTHO CONNECT ®) and (9) the industry-leading, award-winning combination of service, expertise, technology and data-driven solutions that drives effective, efficient labs (Ortho Care ® Services & Informatics). Our core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, molecular assay development, lab-based in vitro diagnostics, blood bank solutions and transfusion pre-screening. Our customized solutions deliver affordability, efficiency, and automation – all supported by an award-winning, service and support program that provides best-in-class technical, field, and remote service in more than 130 countries and territories around the globe. Hospitals, hospital networks, clinical laboratories and blood banks around the world depend on our innovative technology and tools (including our exclusive dry-slide technology) to help ensure test results are fast, accurate, and reliable. We also have well-established track records for providing high-quality products and services to the global clinical laboratory and immunohematology communities. Our sophisticated yet simple-to-use point-of-care tests enable clinicians to chart a course of treatment and empower people to take charge of their health. Today, QuidelOrtho’s comprehensive product portfolio covers a wide range of point-of-care tests for infectious diseases, critical cardiac health and autoimmune biomarkers, and a host of clinical and at-home products to detect COVID-19. And we stood at the forefront of diagnostics innovation throughout the coronavirus pandemic, developing one of the earliest molecular PCR assays for SARS-CoV-2, the first FDA emergency use authorized rapid antigen test that delivers results in 15 minutes, and high-volume antibody and antigen tests for COVID-19. We engineered a patented dry-slide technology that has been revolutionary in both reducing the cost and extending the reach of IVD testing. We also developed the world’s first tests for the detection of antibodies against HIV and hepatitis C. We introduced the first FDA approved rapid antigen diagnostic test for Influenza A and Influenza B and launched the first-ever product to determine Rh+ or Rh- blood type.
We were a pioneer in women’s health diagnostics, developing the earliest lateral-flow pregnancy test strips. Headquartered in San Diego, our company has a rich heritage of innovation and invention.
We combine industry-leading expertise in immunoassay and molecular testing with a global footprint in point-of-care settings, clinical labs and transfusion medicine to advance critical diagnostic solutions at scale. Ranked among the world’s largest in vitro diagnostics (IVD) providers, QuidelOrtho is building on more than 120 years of collective experience and innovation. QuidelOrtho Corporation (Nasdaq: QDEL) unites the power of Quidel Corporation and Ortho Clinical Diagnostics behind a shared mission of developing and manufacturing innovative technologies that raise the performance of diagnostic testing and create better patient outcomes across the entire healthcare continuum.
0 kommentar(er)
